


Recurrent SCLC (i.e. second-line therapy and beyond)



LLCG/VZN annotations

1. Omit IV Topotecan. For oral Topotecan eligible patients should have relapse after 45-180 days of last chemotherapy
2. Add: temozolomide is a potential option. Add: consider clinical trial.
3. Lurbinectedin is not available in Belgium